Paul F Mckay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/93702/publications.pdf Version: 2024-02-01



DALLE F MCKAY

#	Article	IF	CITATIONS
1	Seasonal Betacoronavirus Antibodies' Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. Journal of Clinical Immunology, 2022, 42, 448-458.	3.8	7
2	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Reports, 2022, 38, 110344.	6.4	46
3	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine, 2022, 44, 101262.	7.1	87
4	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 2022, 302, 114475.	2.1	8
5	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity. Journal of Extracellular Vesicles, 2022, 11, e12199.	12.2	14
6	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine, 2022, 40, 2848-2855.	3.8	7
7	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	6.0	2
8	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. Journal of Controlled Release, 2021, 330, 1250-1261.	9.9	28
9	Next-generation COVID-19 vaccines: here come the proteins. Lancet, The, 2021, 397, 643-645.	13.7	9
10	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Molecular Therapy, 2021, 29, 1174-1185.	8.2	40
11	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nature Communications, 2021, 12, 2893.	12.8	104
12	Chlamydia trachomatis: Cell biology, immunology and vaccination. Vaccine, 2021, 39, 2965-2975.	3.8	32
13	Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. Molecular Therapy - Nucleic Acids, 2021, 25, 483-493.	5.1	13
14	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. Journal of Controlled Release, 2021, 338, 201-210.	9.9	53
15	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	4.8	6
16	Isolating Pathogen-Specific Human Monoclonal Antibodies (hmAbs) Using Bacterial Whole Cells as Molecular Probes. Methods in Molecular Biology, 2021, 2183, 9-18.	0.9	1
17	Use of Chlamydial Elementary Bodies as Probes to Isolate Pathogen-Specific Human Monoclonal Antibodies. Methods in Molecular Biology, 2021, 2183, 19-28.	0.9	0
18	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. EBioMedicine, 2020, 59, 102853.	6.1	12

PAUL F MCKAY

#	Article	IF	CITATIONS
19	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non–Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. Journal of Immunology, 2020, 204, 903-913.	0.8	8
20	Neutrophils Enable Local and Nonâ€Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart. Advanced Materials, 2020, 32, e2003598.	21.0	66
21	Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers. Polymer Chemistry, 2020, 11, 3768-3774.	3.9	8
22	The <i>In Vitro</i> , <i>Ex Vivo</i> , and <i>In Vivo</i> Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA. Biomacromolecules, 2020, 21, 3242-3253.	5.4	20
23	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nature Communications, 2020, 11, 3523.	12.8	357
24	Mannosylated Poly(ethylene imine) Copolymers Enhance saRNA Uptake and Expression in Human Skin Explants. Biomacromolecules, 2020, 21, 2482-2492.	5.4	30
25	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. ACS Nano, 2020, 14, 5711-5727.	14.6	92
26	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Therapy, 2019, 26, 363-372.	4.5	137
27	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. Journal of Controlled Release, 2019, 304, 65-74.	9.9	30
28	The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. ACS Nano, 2019, 13, 5920-5930.	14.6	44
29	Identification of potential biomarkers of vaccine inflammation in mice. ELife, 2019, 8, .	6.0	25
30	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. Npj Vaccines, 2018, 3, 2.	6.0	17
31	One Size Does Not Fit All: The Effect of Chain Length and Charge Density of Poly(ethylene imine) Based Copolymers on Delivery of pDNA, mRNA, and RepRNA Polyplexes. Biomacromolecules, 2018, 19, 2870-2879.	5.4	51
32	A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization. Protein Expression and Purification, 2018, 149, 43-50.	1.3	15
33	Structural Components for Amplification of Positive and Negative Strand VEEV Splitzicons. Frontiers in Molecular Biosciences, 2018, 5, 71.	3.5	31
34	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. Cell Reports, 2018, 24, 3324-3338.e5.	6.4	49
35	Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2018, 9, 1784.	4.8	22
36	Advances in HIV-1 Vaccine Development. Viruses, 2018, 10, 167.	3.3	56

PAUL F MCKAY

#	Article	IF	CITATIONS
37	Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. Frontiers in Immunology, 2018, 9, 301.	4.8	18
38	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. Journal of Controlled Release, 2017, 249, 74-83.	9.9	18
39	Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris. AMB Express, 2017, 7, 70.	3.0	14
40	Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry–Based Ig Capture Assay. Journal of Immunology, 2017, 199, 4180-4188.	0.8	37
41	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Frontiers in Immunology, 2017, 8, 149.	4.8	35
42	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology, 2017, 8, 595.	4.8	20
43	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. Frontiers in Immunology, 2017, 8, 1883.	4.8	13
44	Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses. Wellcome Open Research, 2017, 2, 97.	1.8	6
45	A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance. Frontiers in Immunology, 2016, 7, 162.	4.8	24
46	CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice. Journal of Controlled Release, 2016, 232, 75-82.	9.9	4
47	TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes. PLoS ONE, 2016, 11, e0148984.	2.5	27
48	Discrete partitioning of HIV-1 Env forms revealed by viral capture. Retrovirology, 2015, 12, 81.	2.0	16
49	Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. PLoS ONE, 2015, 10, e0141209.	2.5	20
50	Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice. PLoS ONE, 2015, 10, e0141557.	2.5	6
51	Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. Journal of Virology, 2014, 88, 6959-6969.	3.4	32
52	Combinations of TLR4 and TLR7/8 Adjuvants Administered via the ID or IN Routes Generate Different Vaccine Antigen-specific Immune Outcomes in Minipigs. AIDS Research and Human Retroviruses, 2014, 30, A194-A195.	1.1	0
53	Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen. PLoS ONE, 2014, 9, e84707.	2.5	36
54	Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. Journal of Controlled Release, 2013, 170, 452-459.	9.9	36

PAUL F MCKAY

#	Article	IF	CITATIONS
55	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. Journal of Virology, 2013, 87, 890-899.	3.4	23
56	Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice. PLoS ONE, 2013, 8, e67412.	2.5	19
57	Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. Vaccine, 2012, 30, 2778-2785.	3.8	5
58	Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. Journal of Controlled Release, 2012, 162, 529-537.	9.9	80
59	Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine, 2011, 29, 1421-1430.	3.8	39
60	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine, 2011, 29, 4512-4520.	3.8	27
61	Evidence of NK cell dysfunction in SIV-infected rhesus monkeys: Impairment of cytokine secretion and NKG2C/C2 expression. European Journal of Immunology, 2006, 36, 2424-2433.	2.9	34
62	Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. Immunology, 2005, 116, 050920031238006.	4.4	15
63	Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. European Journal of Immunology, 2004, 34, 1011-1020.	2.9	69
64	Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. Journal of Clinical Investigation, 2004, 114, 1334-1342.	8.2	105
65	Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. Journal of Clinical Investigation, 2004, 114, 1334-1342.	8.2	62
66	Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines. Journal of Virology, 2003, 77, 8729-8735.	3.4	120
67	Global Dysfunction of CD4 T-Lymphocyte Cytokine Expression in Simian-Human Immunodeficiency Virus/SIV-Infected Monkeys Is Prevented by Vaccination. Journal of Virology, 2003, 77, 4695-4702.	3.4	26
68	Vaccine Protection Against Functional CTL Abnormalities in Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Immunology, 2002, 168, 332-337.	0.8	38
69	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. Journal of Virology, 2002, 76, 11484-11490.	3.4	47
70	Flow Cytometric Analysis. Methods in Molecular Medicine, 2000, 40, 407-414.	0.8	8
71	The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. European Journal of Immunology, 1998, 28, 4071-4083.	2.9	31
72	Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial. SSRN Electronic Journal, 0, , .	0.4	13

#	Article	IF	CITATIONS
73	Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses. Wellcome Open Research, 0, 2, 97.	1.8	6
74	Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility. SSRN Electronic Journal, 0, , .	0.4	3